![]() ![]() To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. Guidelines and recommendations PMID: 33199880 AbstractĪcademic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. Improving target assessment in biomedical research: the GOT-IT recommendations. and the PAASP GmbH (Partnership for Assessment and Accreditation of Scientific Practice) in Heidelberg.Įmmerich CE, Martinez-Gamboa L, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, Gerlach B, Hempel K, Bespalov A, Dirnagl U, Parnham MJ. The GOT-IT team consists of working groups from the Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, the Translational Drug Validation and Preclinical Disease Models group at the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME-TMP) in Frankfurt a.M. Dissemination and sustainability of the recommendations will be facilitated via an Educational as well as Online Expert Platform. The GOT-IT recommendations have been refined through communication with the experts from the broad research community (including pharma, biotech, technology transfer, funders), especially also with the individual 'Target Validation' teams within the BMBF Target Validation for Drug Development program. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is expected to stimulate academic scientists' awareness of which factors are important to generate robust and high-quality research outcomes and to facilitate academia-industry collaborations. To support the shift from purely academic exploration to the initiation of formal drug discovery the GOT-IT recommendations help in identifying and prioritizing relevant target assessment activities and in defining a critical path to reach scientific as well as goals related to licensing, partnering with industry or initiating clinical development programs. In addition, however, the successful translation of basic research findings into new therapeutics often requires that further areas and aspects are addressed like target-related safety issues, druggability and assayability, as well as differentiation from established or emerging therapies, which are summarized as 'target assessment' in the context of the GOT-IT project. ![]() The validation of these molecules based on solid quality criteria is a pivotal step for the development of potential new drug compounds, before they can be considered for use in clinical studies. This kind of research is usually conducted at academic institutions. The basis for the development of new drug compounds is the identification of disease-modulating molecules, so called targets. Guidelines on Target Assessment for Innovative TherapeuticsĬontinuous biomedical research and development of new drug compounds contribute to the maintenance of good medical care through innovative therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |